Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 5 Ureteral Neoplasms 3 Neoplasm Metastasis 2 Metastatic Urothelial Cancer 2 Urologic Neoplasms 1 Urethral Neoplasms 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Muscle-invasive Bladder Cancer 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1 Adenocarcinoma of the Bladder 1

Interventions

Ipilimumab 106 Nivolumab 101 pembrolizumab 90 aldesleukin 72 Cyclophosphamide 46 Interleukin-2 45 Temozolomide 36 Dacarbazine 32 trametinib 31 dabrafenib 30 fludarabine phosphate 29 incomplete Freund's adjuvant 27 Bevacizumab 26 sargramostim 25 Vemurafenib 25 fludarabine 22 binimetinib 21 Radiosurgery 21 Paclitaxel 20 encorafenib 19 Carboplatin 19 CTLA-4 Antigen 18 cobimetinib 16 atezolizumab 15 Radiotherapy 14 Biopsy 14 Sorafenib 13 MART-1 Antigen 12 talimogene laherparepvec 11 montanide ISA 51 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × enfortumab vedotin × Clear all

NCT06906822 2025-09-18

PlugIN

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡